Status:
COMPLETED
A Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Unit (ICU) Patients
Lead Sponsor:
Austin Health
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Meropenem is a powerful antibiotic used in intensive care for people who have very serious infections. Meropenem is rapidly removed from the blood by the kidneys and it is very expensive. In very ill ...
Detailed Description
The use of pharmacodynamic and pharmacokinetic principles in antibiotic dosing is advocated to enable more effective and efficient use of antibiotics. The current standard of care in Austin ICU is to...
Eligibility Criteria
Inclusion
- Adult intensive care patients
- Predicted duration of treatment 3 days or more
Exclusion
- Predicted duration of treatment less than 3 days
- Hypersensitivity to meropenem or other beta-lactams
- Consent unable to be obtained by participant or next of kin
- Suspected or proven bacterial meningitis
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00891423
Start Date
April 1 2009
End Date
January 1 2010
Last Update
August 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Austin Health
Melbourne, Victoria, Australia, 3084